Background: There are indications that low S-25(OH)D is associated with increased disease severity in psychotic disorder, but there is still uncertain whether low levels are associated with a specific symptom profile. Our first aim was to investigate the relations between low S-25(OH)D and positive, negative and depressive symptoms. Our second aim was to explore if associations between S-25(OH)D and symptoms were influenced by levels of inflammatory markers. 
Introduction
Vitamin D is a fat-soluble hormone that recent years has been found important for neurodevelopment and for neuropsychiatric disorders (Cui et al., 2015) . It passes the blood-brain barrier, and both the vitamin D receptor (VDR) and the enzyme that hydroxylates the circulating form S-25(OH)D into the active metabolite 1,25-dihydroxy-vitamin D (1,25(OH) 2 D) are found in the human brain (Eyles et al., 2005) . The prevalence of vitamin D deficiency is reported to be high in psychotic disorders (Belvederi Murri et al., 2013; Valipour et al., 2014) and this could infuence on symptoms.
Low S-25(OH)D has been found in patients with acute psychotic episodes compared to patients in remission (Yuksel et al., 2014) and in acute psychosis with excitement or stupor, bizarre and disorganized behaviour (Dealberto, 2013) . There has been proposed sex differenses where low vitamin D has been found associated with negative symptoms in males, and to increased anti-social aggression in females (Cieslak et al., 2014a) . Low vitamin D levels have also been found associated with higher degree of negative symptoms like social anhedonia and poverty of speech in males (Cieslak et al., 2014a ) and the total negative symptom factor in a first episode sample (Graham et al., 2014) . The strongest link between low S-25(OH)D and psychiatric symptomatology has been found in depression (Anglin et al., 2013; Milaneschi et al., 2014) . In line with this, suicide attempters have significantly lower S-25(OH)D compared to non-suicidal patients (Grudet et al., 2014) . Many patients with psychotic disorders experience depressive episodes (Romm et al., 2010) and previous findings indicate that low S-25(OH)D is associated with depression also in psychotic disorders .
Vitamin D is found to be a regulator of the immune system (Calton et al., 2015; Fernandes de Abreu et al., 2009 ) and low S-25(OH)D has been found associated with increased inflammation in schizophrenia patients compared to controls. Inflammation is investigated as a potential general disease mechanism in severe psychotic disorders (Goldstein et al., 2009; Potvin et al., 2008) . In animal models vitamin D is considered to have anti-inflammatory neuroprotective properties in the brain through recruitment of microglia (Garcion et al., 1998) and immune-regulation through dendritic cells (Bscheider and Butcher, 2016) , and it is possible that the relation between low S-25(OH)D and clinical symptoms could be influenced by inflammatory pathways (Autier et al., 2014) .
Previous publications from our research group have shown associations between psychotic symptomatology and increased levels of the inflammatory markers soluble tumor necrosis factor receptor 1 (sTNF-R1) and interleukin-1 receptor antagonist (IL-1Ra) (Hope et al., 2013) in both schizophrenia and bipolar disorder, and between depressed mood and low levels of the inflammatory markers osteoprotegerin (OPG), sTNF-R1 and IL-1Ra in bipolar disorder (Hope et al., 2011) .
There are thus indications that low S-25(OH)D is associated with increased disease severity in psychotic disorder, but there is still uncertain whether low levels are associated with a specific symptom profile . It is also uncertain whether the associations between vitamin D and disease activitity is associated with levels of inflammatory markers. Our first aim was to investigate the relations between low S-25(OH)D and symptom profiles in a large, well-categorized clinical sample of patients with psychotic disorders. We more specifically wanted to test if low S-25(OH)D was associated with increased positive or negative symptoms as measured by the Positive and Negative Syndrome scale for Schizophrenia (PANSS) and with increased depressive and suicidal symptoms as measured by the Calgary Depression Scale for Schizophrenia (CDSS). Our second aim was to explore if associations between S-25(OH)D and symptom profiles were influenced by general inflammation measured by C-reactive protein (CRP) or the level of the inflammatory markers; sTNF-R1, IL-1Ra and OPG, markers found to be related to positive symptoms in psychotic disorder and with depression in bipolar disorder. (Kay et al., 1987) . PANSS scores were analyzed using Wallwork's five -factor model, (Wallwork et al., 2012) . This fivefactor model is found to be appropriate in clinical samples of different cultural background (Wallwork et al., 2012) and in early psychosis (Langeveld et al., 2012) . It can be difficult to distinguish between depressive and negative symptomatology in patients with psychotic disorders. The Calgary Depression Scale for Schizophrenia (CDSS) was developed to identify depression in patients with psychosis by excluding symptoms that overlap with negative symptoms of schizophrenia (Addington et al., 1992; Addington et al., 1990) and it thus differentiates better than other depression scales (Addington et al., 1994) . We lacked CDSS information for 71 participants who instead had been assessed using the clinician-rated Inventory of Depressive Symptomatology (IDS-C) (Rush et al., 1996) .
Their IDS-C scores were used to impute the missing data (see paragraph 2.3). Current suicidal ideation was derived from item 8 from CDSS and item 18 from IDS-C and subsequently dichotomized into no suicidal ideation as "0" and mild, moderate and severe suicidal ideation as "1". Age of onset was set as age at the time of the first psychotic episode, and duration of illness was calculated as age at inclusion into the study minus age of onset. The seasons were dichotomized into winter (December -May) and summer (June-November) (Porojnicu et al., 2007) . Ethnicity was determined by asking for country of birth for the participant and his/her parents and was used to divide the participants into two groups; the majority population group (including participants with European ancestry) and the ethnic minority group (including participants with Asian, Latin -American and African ancestry). At inclusion the participants went through a physical examination including blood sampling; a standard procedure was used to measure height and weight and body mass index (BMI) calculated by kg/m². The participants were asked for their total use and prescriptions of medications.
Biochemical variables
From September 2012; total S-25(OH)D (a sum of 25(OH)D2 and 25(OH)D3) was determined using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method developed at the Hormone laboratory (Oslo University Hospital, Aker) (Nerhus et al., 2015) . Until September 2012, S-25(OH)D was measured by radioimmunoassay (RIA kit from Diasorin) (Holvik et al., 2005) (Hope et al., 2015) . IL-1Ra is a regulator of IL-1α activity; sTNF-R1 is a marker of activity in upstream inflammatory pathways and OPG is a soluble member of the tumor necrosis family (Dieset et al., 2012) . CRP in plasma, serum -thyroxine (T4) and thyroid stimulating hormone (TSH) were analyzed at Department of clinical Biochemistry (Oslo University Hospital, Ullevaal). Three participants had CRP >20 mg/L (i.e. suspect of inter-current infection) and two had known chronic infections (hepatitis) and were removed from the analysis for the second research aim.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics v. 22 (IBM Corp. 2014) . The level of significance was preset to p < 0.05 (two-tailed). For the participants missing CDSS scores, the score was imputed based on a regression model developed from a subsample of 146 patients with both IDS-C and CDSS scores, producing the following formula; (-0,314) + (IDS-C x 0,282) (adjusted R 2 = 67.1). We used mean substitution for missing data (4 missing for years of education, 3 missing hospitalization status and 14 missing T4 measurements). The bivariate correlations were evaluated with Pearson's r for the dichotomous and continuous variables with normal distribution and with Spearman's rho for the variables with skewed distribution. The positive and negative symptom factors from the PANSS and CRP were log-transformed, and the CDSS total score was square root transformed to be able to use regression as the main analytic strategy in multivariate analyses. We performed additional analysis straftified by gender and found a trend for bivariate correlation between low vitamin D and higher score on the disorganized symptom factor in women (Pearson's r=-0.14, p=0.06), however in multiple regression this association was non-significant (t=-0.13, p=0.90).
Discussion
Our main finding from this large sample of participants with broad DSM-IV psychotic disorders was that low S-25(OH)D was associated with higher levels of negative symptoms and of depression, also when controlling for potential confounding factors.
The significant association between low S-25(OH)D and higher negative symptom factor expand the knowledge from two previous small studies that have found the same association (Cieslak et al., 2014b; Graham et al., 2014) . The findings are of great clinical relevance since negative symptoms have an even higher impact on impaired quality of life than positive symptoms (Faerden et al., 2009; Fervaha et al., 2014) and we lack possible treatment strategies (Tsapakis et al., 2015) .
The association between S-25(OH)D and positive symptoms was not l significant after controlling for education and diagnosis. Associations between low S-25(OH)D andpositive symptoms have been found in studies of youths with psychiatric disorders (Gracious et al., 2012) and in acute psychosis (Yuksel et al., 2014) , but the samples from these particular studies may represent a subgroup of patients with more severe symptomatology or other confounders as they were all inpatients.
Associations with florid positive symptoms and atypical syptoms were found in a sample of immigrants with recent refugee background hypothesized tohave a recent drop in vitamin D levels (Dealberto, 2013) . In this particular study however the patients were not yet diagnosed and education level was not taken into account, factors that according to our study are confounders of the association between vitamin D and positive symptoms.
In the current study we also found a significant association between low S-25(OH)D and higher scores for depressive symptoms. This is in line with results from clinical samples of psychotic disorder and depressive disorders (Milaneschi et al., 2014) . Suicidal ideations were also associated with low S-25(OH)D in the current study in line with another study (Grudet et al., 2014) and the multivariate analyses showed that this association mainly was mediated by depression as expected. In a clinical setting, this could support vitamin D as adjuvant therapy in treating co-morbid depressions in psychotic disorders.
There are several possible explanations for the strong associations between low S-25(OH)D and higher scores on negative and depressive symptoms. We hypothesized that inflammation was a mediating factor. We found that CRP was significantly correlated with both S-25(OH)D and negative symptoms, but the association between S-25(OH)D and negative symptoms was not mediated by CRP in multiple regression. IL-1Ra was bivariate correlated with negative symptoms in line with earlier findings linking IL-1Ra to disease activity (Hope et al., 2011; Hope et al., 2013) , but had no significant association with S-25(OH)D. Our results imply an independent associations between S-25(OH)D and symptomatology not mediated by pro-inflammatory markers. The immune system is however very complex and there could be other interactions between S-25(OH)D , inflammation and symptomatology that is not covered by our analytic strategy or choice of inflammatory markers.
An alternate explanation for the associations between S-25(OH)D and symptoms is that disease behavior may affect vitamin D levels (Belvederi Murri et al., 2013) . It is possible that illness behavior from both negative and depressive symptomatology includes spending more time indoor and having less focus on diet, and the low S-25(OH)D could be interpreted as secondary to the symptomatology.
In our analyses we have controlled for diagnose, hospitalization status and ethnic background, but our data are cross sectional and we cannot conclude regarding direction of the associations.
Randomized controlled trials have been performed in relation to depression. The results are ambiguous, however vitamin D appear to have an anti-depressive effect (Li et al., 2014; Spedding, 2014 ).
There are however indications that vitamin D could be more directly involved in the pathogenesis of specific symptoms. Vitamin D is considered neuroprotective properties through its prevention of oxidative stress in the central nerve system (Wrzosek et al., 2013) and there are hypothesis how oxidative stress may cause negative symptoms (Albayrak et al., 2013) , possibly by imbalance in the excitative-inhibitory glutamate-GABA responses (Sullivan and O'Donnell, 2012) There are also indications that vitamin D is involved in the pathogenesis of depression, possible through the serotonin system, as vitamin D recently has been discovered as a regulator of the serotonin synthesis (Patrick and Ames, 2014) . The observed seasonality in affective disorders also implicates an important role for sun exposure and vitamin D in depression (Akhter et al., 2013; Geoffroy et al., 2014 ).
An important strength of the current study is that we have a large, well-characterized sample. The participants are recruited from in-and outpatient clinics from a catchment area based health care system providing a broad spectrum of psychotic disorder with participants from all parts of the society. This makes the sample representative and we can adjust for possible confounding factors.
Important limitations are that two different assays were used for S-25(OH)D measurements and we did not have full datasets available for all the variables incorporated in the analyses. For CDSS however we were able to impute the missing values based on IDS-C. Only a subgroup had available immune measurements and a partial effect from the inflammatory markers cannot be excluded.
In conclusion, there are strong associations between lower S-25(OH)D and increased negative and depressive symptoms in psychotic disorders. Randomized controlled trials should be performed to investigate the effect of vitamin D supplementation as a possible adjuvant treatment strategy in this patient group. 
